Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD Jr, Kuehl WM, Staudt LM.

Cancer Cell. 2007 Aug;12(2):115-30.

2.

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, Braggio E, Henry T, Zhu YX, Fogle H, Price-Troska T, Ahmann G, Mancini C, Brents LA, Kumar S, Greipp P, Dispenzieri A, Bryant B, Mulligan G, Bruhn L, Barrett M, Valdez R, Trent J, Stewart AK, Carpten J, Bergsagel PL.

Cancer Cell. 2007 Aug;12(2):131-44.

3.

Classical and/or alternative NF-kappaB pathway activation in multiple myeloma.

Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM.

Blood. 2010 Apr 29;115(17):3541-52. doi: 10.1182/blood-2009-09-243535. Epub 2010 Jan 6.

4.

Negative feedback in noncanonical NF-kappaB signaling modulates NIK stability through IKKalpha-mediated phosphorylation.

Razani B, Zarnegar B, Ytterberg AJ, Shiba T, Dempsey PW, Ware CF, Loo JA, Cheng G.

Sci Signal. 2010 May 25;3(123):ra41. doi: 10.1126/scisignal.2000778.

5.

Maximal adamantyl-substituted retinoid-related molecule-induced apoptosis requires NF-κB noncanonical and canonical pathway activation.

Farhana L, Dawson MI, Murshed F, Fontana JA.

Cell Death Differ. 2011 Jan;18(1):164-73. doi: 10.1038/cdd.2010.84. Epub 2010 Jul 30.

6.

Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways.

Pham LV, Fu L, Tamayo AT, Bueso-Ramos C, Drakos E, Vega F, Medeiros LJ, Ford RJ.

Blood. 2011 Jan 6;117(1):200-10. doi: 10.1182/blood-2010-06-290437. Epub 2010 Oct 1.

7.

Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.

Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, Meissner B, Bhang HE, Ruddy D, Kauffmann A, Farsidjani A, Derti A, Rakiec D, Naylor T, Pfister E, Kovats S, Kim S, Dietze K, Dörken B, Steidl C, Tzankov A, Hummel M, Monahan J, Morrissey MP, Fritsch C, Sellers WR, Cooke VG, Gascoyne RD, Lenz G, Stegmeier F.

Nat Med. 2014 Jan;20(1):87-92. doi: 10.1038/nm.3435. Epub 2013 Dec 22.

PMID:
24362935
8.

XEDAR activates the non-canonical NF-κB pathway.

Verhelst K, Gardam S, Borghi A, Kreike M, Carpentier I, Beyaert R.

Biochem Biophys Res Commun. 2015 Sep 18;465(2):275-80. doi: 10.1016/j.bbrc.2015.08.019. Epub 2015 Aug 8.

PMID:
26260321
9.

Control of canonical NF-kappaB activation through the NIK-IKK complex pathway.

Zarnegar B, Yamazaki S, He JQ, Cheng G.

Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3503-8. doi: 10.1073/pnas.0707959105. Epub 2008 Feb 21.

10.

Specificity of TRAF3 in its negative regulation of the noncanonical NF-kappa B pathway.

He JQ, Saha SK, Kang JR, Zarnegar B, Cheng G.

J Biol Chem. 2007 Feb 9;282(6):3688-94. Epub 2006 Dec 11.

11.

Noncanonical NF-κB signaling is limited by classical NF-κB activity.

Gray CM, Remouchamps C, McCorkell KA, Solt LA, Dejardin E, Orange JS, May MJ.

Sci Signal. 2014 Feb 4;7(311):ra13. doi: 10.1126/scisignal.2004557.

12.

A fourth IkappaB protein within the NF-kappaB signaling module.

Basak S, Kim H, Kearns JD, Tergaonkar V, O'Dea E, Werner SL, Benedict CA, Ware CF, Ghosh G, Verma IM, Hoffmann A.

Cell. 2007 Jan 26;128(2):369-81.

13.

A roadmap of constitutive NF-κB activity in Hodgkin lymphoma: Dominant roles of p50 and p52 revealed by genome-wide analyses.

de Oliveira KA, Kaergel E, Heinig M, Fontaine JF, Patone G, Muro EM, Mathas S, Hummel M, Andrade-Navarro MA, Hübner N, Scheidereit C.

Genome Med. 2016 Mar 17;8(1):28. doi: 10.1186/s13073-016-0280-5.

14.

Methods to assess the activation of the alternative (noncanonical) NF-κB pathway by non-death TNF receptors.

Remouchamps C, Dejardin E.

Methods Mol Biol. 2015;1280:103-19. doi: 10.1007/978-1-4939-2422-6_7.

PMID:
25736746
15.

LATS2 inhibits the activity of NF-κ B signaling by disrupting the interaction between TAK1 and IKKβ.

Yao F, Zhou W, Zhong C, Fang W.

Tumour Biol. 2015 Sep;36(10):7873-9. doi: 10.1007/s13277-015-3362-x. Epub 2015 May 7.

PMID:
25946971
16.

TACI induces cIAP1-mediated ubiquitination of NIK by TRAF2 and TANK to limit non-canonical NF-kappaB signaling.

Kanno Y, Sakurai D, Hase H, Kojima H, Kobata T.

J Recept Signal Transduct Res. 2010 Apr;30(2):121-32. doi: 10.3109/10799891003634509.

PMID:
20184394
17.

TRAF3 controls activation of the canonical and alternative NFkappaB by the lymphotoxin beta receptor.

Bista P, Zeng W, Ryan S, Bailly V, Browning JL, Lukashev ME.

J Biol Chem. 2010 Apr 23;285(17):12971-8. doi: 10.1074/jbc.M109.076091. Epub 2010 Feb 25.

18.

An atypical E3 ligase zinc finger protein 91 stabilizes and activates NF-kappaB-inducing kinase via Lys63-linked ubiquitination.

Jin X, Jin HR, Jung HS, Lee SJ, Lee JH, Lee JJ.

J Biol Chem. 2010 Oct 1;285(40):30539-47. doi: 10.1074/jbc.M110.129551. Epub 2010 Aug 3.

19.

Regulation of activity and function of the p52 NF-κB subunit following DNA damage.

Barré B, Coqueret O, Perkins ND.

Cell Cycle. 2010 Dec 15;9(24):4795-804. Epub 2010 Dec 15. Retraction in: Cell Cycle. 2014;13(14):2312.

PMID:
21131783
20.

CD40 regulates the processing of NF-kappaB2 p100 to p52.

Coope HJ, Atkinson PG, Huhse B, Belich M, Janzen J, Holman MJ, Klaus GG, Johnston LH, Ley SC.

EMBO J. 2002 Oct 15;21(20):5375-85.

Supplemental Content

Support Center